Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Oramed Pharma Signs $50 Million Diabetes Deal with Sinopharm

publication date: Jul 7, 2015
In a dramatic turnaround, Oramed Pharma of Jerusalem signed a LOI to complete a $50 million deal for China rights to its clinical-stage oral insulin with Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development Co. Last week, Oramed announced a similar deal (though not identical) with Wuzhou Zhongheng Group, an agreement that apparently fell apart. Sinopharm/Hefei paid $500,000 for 60 days of exclusive talks with Oramed, while final terms of the agreement are negotiated. More details....

Stock Symbols: (NSDQ: ORMP) (SHA: 600252)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital